Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Sporos Bioventures
Deal Size : $15.5 million
Deal Type : Series A Financing
Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing
Details : Stellanova’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 06, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Sporos Bioventures
Deal Size : $15.5 million
Deal Type : Series A Financing